Recombinant Mouse Flt‑3 Ligand/FLT3L (Catalog # 427-FL) stimulates proliferation in BaF3 mouse pro‑B cell line transfected with mouse Flt‑3 in a dose-dependent manner (orange line). Proliferation ...read more
Flt‑3 Ligand/FLT3L was detected in immersion fixed HT‑2 mouse T cell line using Goat Anti-Mouse Flt‑3 Ligand/FLT3L Antigen Affinity-purified Polyclonal Antibody (Catalog # AF427) at 5 µg/mL ...read more
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
Reconstitute at 0.2 mg/mL in sterile PBS.
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Flt-3 Ligand/FLT3L Antibody [Unconjugated]
fms-related tyrosine kinase 3 ligand
Flt-3 Ligand, also known as FL, is an alpha -helical cytokine that promotes the differentiation of multiple hematopoietic cell lineages (1‑3). Mature mouse Flt-3 Ligand consists of a 161 amino acid (aa) extracellular domain (ECD) with a cytokine-like domain and a juxtamembrane tether region, a 21 aa transmembrane segment, and a 22 aa cytoplasmic tail (4‑6). Within the ECD, mouse Flt-3 Ligand shares 71% and 81% aa sequence identity with human and rat Flt-3 Ligand, respectively. Mouse and human Flt-3 Ligand show cross-species activity (4, 5, 7). Flt-3 Ligand is expressed as a noncovalently-linked dimer by T cells and bone marrow and thymic fibroblasts (1, 8). Each 36 kDa chain carries approximately 12 kDa of N- and O-linked carbohydrates (8). Alternate splicing and proteolytic cleavage of the transmembrane form can generate a soluble 30 kDa fragment that includes the cytokine domain (4, 8). Alternate splicing of mouse Flt-3 Ligand also generates a membrane-associated isoform with a 57 aa substitution following the cytokine domain (4, 5, 8, 9). Both transmembrane and soluble Flt-3 Ligand signal through the tyrosine kinase receptor Flt-3/Flk-2 (3‑6). Flt-3 Ligand induces the expansion of monocytes and immature dendritic cells as well as early B cell lineage differentiation (2, 10). It synergizes with IL-3, GM-CSF, and SCF to promote the mobilization and myeloid differentiation of hematopoietic stem cells (4, 5, 7). It cooperates with IL-2, -6, -7, and -15 to induce NK cell development and with IL-3, -7, and -11 to induce terminal B cell maturation (1, 11). Animal studies also show Flt-3 Ligand to reduce the severity of experimentally induced allergic inflammation (12).
Wodnar-Filipowicz, A. (2003) News Physiol. Sci. 18:247.
Dong, J. et al. (2002) Cancer Biol. Ther. 1:486.
Gilliland, D.G. and J.D. Griffin (2002) Blood 100:1532.
Hannum, C. et al. (1994) Nature 368:643.
Lyman, S.D. et al. (1993) Cell 75:1157.
Savvides, S.N. et al. (2000) Nat. Struct. Biol. 7:486.
Lyman, S.D. et al. (1994) Blood 83:2795.
McClanahan, T. et al. (1996) Blood 88:3371.
Lyman, S.D. et al. (1995) Oncogene 10:149.
Diener, K.R. et al. (2008) Exp. Hematol. 36:51.
Farag, S.S. and M.A. Caligiuri (2006) Blood Rev. 20:123.
Edwan, J.H. et al. (2004) J. Immunol. 172:5016.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our Flt-3 Ligand/FLT3L Antibody [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.